- Home
- HKIT vs PRLD Comparison
HKIT vs PRLD Comparison
Compare HKIT & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HKIT
- PRLD
- Stock Information
- Founded
- HKIT 1996
- PRLD 2016
- Country
- HKIT China
- PRLD United States
- Employees
- HKIT N/A
- PRLD N/A
- Industry
- HKIT Computer Software: Prepackaged Software
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- HKIT Technology
- PRLD Health Care
- Exchange
- HKIT Nasdaq
- PRLD Nasdaq
- Market Cap
- HKIT 45.4M
- PRLD 53.4M
- IPO Year
- HKIT 2023
- PRLD 2020
- Fundamental
- Price
- HKIT $1.38
- PRLD $0.91
- Analyst Decision
- HKIT
- PRLD Buy
- Analyst Count
- HKIT 0
- PRLD 3
- Target Price
- HKIT N/A
- PRLD $4.33
- AVG Volume (30 Days)
- HKIT 24.4K
- PRLD 455.0K
- Earning Date
- HKIT 12-31-2024
- PRLD 11-06-2024
- Dividend Yield
- HKIT N/A
- PRLD N/A
- EPS Growth
- HKIT N/A
- PRLD N/A
- EPS
- HKIT 0.04
- PRLD N/A
- Revenue
- HKIT $3,449,206.00
- PRLD $3,000,000.00
- Revenue This Year
- HKIT N/A
- PRLD N/A
- Revenue Next Year
- HKIT N/A
- PRLD N/A
- P/E Ratio
- HKIT $35.50
- PRLD N/A
- Revenue Growth
- HKIT N/A
- PRLD N/A
- 52 Week Low
- HKIT $0.54
- PRLD $0.80
- 52 Week High
- HKIT $6.48
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- HKIT 48.72
- PRLD 37.34
- Support Level
- HKIT $1.31
- PRLD $0.80
- Resistance Level
- HKIT $1.61
- PRLD $1.13
- Average True Range (ATR)
- HKIT 0.09
- PRLD 0.09
- MACD
- HKIT 0.01
- PRLD 0.02
- Stochastic Oscillator
- HKIT 27.78
- PRLD 32.82
About HKIT Hitek Global Inc.
Hitek Global Inc is a provider of information technology consulting and solutions services. The company has two lines of businesses such as services to small and medium businesses, which consist of Anti-Counterfeiting Tax Control System tax devices, including Golden Tax Disk and printers, ACTCS services, and IT services; and services to large businesses, which include hardware sales and software sales. It generates revenues from hardware sales, software sales, IT services, and tax devices and services.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.